The Role of Immunotherapy or Immuno-Chemotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
暂无分享,去创建一个
F. Petrella | M. Casiraghi | D. Galetta | L. Spaggiari | F. de Marinis | L. Bertolaccini | S. Mohamed
[1] T. Mok,et al. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722 , 2022, Annals of Oncology.
[2] J. Bosch-Barrera,et al. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study , 2022, Journal of Thoracic Oncology.
[3] M. Tsuboi,et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. , 2022, The Lancet. Oncology.
[4] U. Dafni,et al. 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091 , 2022, Annals of Oncology.
[5] A. Chella,et al. PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC , 2022, Journal of Thoracic Oncology.
[6] Juliana Guarize,et al. The Interdisciplinary Management of Lung Cancer in the European Community , 2022, Journal of clinical medicine.
[7] Robert W. Hsieh,et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. , 2022, The Lancet. Oncology.
[8] R. Herbst,et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] N. Girard,et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.
[10] A. Chella,et al. 80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study , 2022, Annals of Oncology.
[11] D. Planchard,et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Addeo,et al. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. , 2022, Cancer treatment reviews.
[13] K. Kerrigan,et al. Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer , 2022, Current Oncology Reports.
[14] N. Reinmuth,et al. PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study , 2021, Journal of Thoracic Oncology.
[15] J. Heymach,et al. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. , 2021, Clinical lung cancer.
[16] A. Chella,et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.
[17] D. Planchard,et al. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations , 2021, Annals of Oncology.
[18] N. Girard,et al. 1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy , 2021, Annals of Oncology.
[19] D. de Ruysscher,et al. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. , 2021, Clinical lung cancer.
[20] Keunchil Park,et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer , 2021, JAMA oncology.
[21] N. Girard,et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). , 2021 .
[22] N. Sanfilippo,et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. , 2021, The Lancet. Oncology.
[23] James D. Murphy,et al. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer , 2021, JAMA network open.
[24] D. Harpole,et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. , 2021, The Journal of thoracic and cardiovascular surgery.
[25] M. Tsuboi,et al. 93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy , 2021 .
[26] C. Faivre-Finn,et al. 78MO Early safety assessment of durvalumab after sCRT in patients with stage III, unresectable NSCLC (PACIFIC-6) , 2021 .
[27] M. Kris,et al. PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis , 2021 .
[28] M. Tsuboi,et al. P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery , 2021 .
[29] Summer S. Han,et al. Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[30] Keunchil Park,et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Kriegsmann,et al. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. , 2021, Lung cancer.
[32] A. Shaw,et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.
[33] U. Dafni,et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] I. Wistuba,et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.
[35] M. Tsuboi,et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.
[36] C. Chiu,et al. 1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC) , 2020 .
[37] B. Milleron,et al. 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO) , 2020 .
[38] E. Fadel,et al. 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial , 2020 .
[39] M. Tsuboi,et al. 1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study , 2020 .
[40] M. Provencio,et al. Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC. , 2020 .
[41] N. Hanna,et al. Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial. , 2020 .
[42] D. Carbone,et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. , 2020 .
[43] P. Jänne,et al. ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. , 2020 .
[44] M. Lanuti,et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.
[45] Edward S. Kim,et al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.
[46] Yibo Gao,et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[47] G. Rossi,et al. Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. , 2020, Critical reviews in oncology/hematology.
[48] P. Fournel,et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[49] D. Planchard,et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[50] K. Syrigos,et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.
[51] K. Boucher,et al. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up , 2019, Targeted Oncology.
[52] A. Drilon,et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] Ying Cheng,et al. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] L. Trani,et al. PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC. , 2019, Journal of Clinical Oncology.
[55] D. Gandara,et al. IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] J. Goldman,et al. KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. , 2019, Translational lung cancer research.
[57] B. Han,et al. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study , 2018, The oncologist.
[58] David R. Jones,et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. , 2019, The Journal of thoracic and cardiovascular surgery.
[59] W. Mao,et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. , 2018, The Lancet. Respiratory medicine.
[60] C. Rudin,et al. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). , 2018 .
[61] Ying Cheng,et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. , 2018, The Lancet. Oncology.
[62] E. Felip,et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[64] V. Rusch,et al. Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. , 2017, The Annals of thoracic surgery.
[65] R. Govindan,et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Li Zhang,et al. Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer , 2017, Medical science monitor : international medical journal of experimental and clinical research.
[67] F. Petrella,et al. Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer. , 2017, Seminars in thoracic and cardiovascular surgery.
[68] M. Stuschke,et al. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence , 2017, Oncotarget.
[69] H. Asamura,et al. The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: past activities, current status and future direction. , 2017, Japanese journal of clinical oncology.
[70] S. Gettinger,et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.
[71] Frank C. Detterbeck,et al. The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.
[72] P. Stephens,et al. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. , 2016, The oncologist.
[73] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[74] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[75] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[76] B. Hutton,et al. The incidence and clinical impact of bone metastases in non-small cell lung cancer. , 2015, Lung cancer.
[77] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[78] Chris Sander,et al. Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.
[79] P. Thomas,et al. Surgical management of advanced non-small cell lung cancer. , 2014, Journal of thoracic disease.
[80] E. Smit,et al. Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010 , 2014, Acta oncologica.
[81] C. Drake,et al. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma , 2011, Clinical Cancer Research.
[82] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[83] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.